STOCK TITAN
  1. Home
  2. News
  3. MOR

Morphosys AG - MOR STOCK NEWS

Welcome to our dedicated news page for Morphosys (Ticker: MOR), a resource for investors and traders seeking the latest updates and insights on Morphosys.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Morphosys's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Morphosys's position in the market.

News
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Rhea-AI Summary
Novartis offers €68.00 per share in cash, totaling €2.7 billion, to acquire MorphoSys AG. Shareholders are recommended to accept the offer by May 13, 2024, with a premium of 94% and 142% on the average price. The acquisition aims to accelerate oncology pipeline development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Rhea-AI Summary
MorphoSys AG receives U.S. antitrust clearance for acquisition by Novartis AG, with a proposed takeover offer of € 68.00 per share, totaling € 2.7 billion. The offer document expected in April 2024, with a minimum acceptance threshold of 65% of share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
acquisition
-
News
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
MorphoSys AG reports positive results for the fourth quarter and full year 2023, showcasing successful Phase 3 MANIFEST-2 study outcomes and significant financial figures. The company entered a Business Combination Agreement with Novartis, aiming to be acquired for € 68.00 per share in cash. Novartis plans to develop and commercialize pelabresib and tulmimetostat globally, with the transaction expected to close in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
earnings
News
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Rhea-AI Summary
MorphoSys AG to release financial year 2023 results on March 13, 2024, with a conference call and webcast scheduled on March 14, 2024. The Management team will present the results and outlook for 2024, followed by a Q&A session. Participants can join via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
News
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Rhea-AI Summary
MorphoSys AG (MOR) has entered into a Business Combination Agreement with Novartis, who will submit a voluntary public takeover offer for all outstanding MorphoSys shares at a price of €68.00 per share in cash. Novartis also seeks exclusive, worldwide rights to develop and commercialize pelabresib and tulmimetostat. Additionally, MorphoSys entered into a Purchase Agreement to sell all rights related to tafasitamab to Incyte. The offer provides shareholders with a 94% premium to the one-month volume weighted average price before January 25, 2024. Novartis will provide resources to maximize pelabresib's potential and MorphoSys' Management Board and Supervisory Board unanimously support both agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
acquisition
-
News
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
News
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Rhea-AI Summary
MorphoSys AG reported preliminary Monjuvi U.S. net product sales of US$ 92.0 million and preliminary gross margin of 69% for 2023. Anticipated 2024 Monjuvi U.S. net product sales are expected to be in the range of US$ 80 to 95 million, with 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million. The company also reduced its financial liability from the collaboration with Incyte by approximately € 112 million. MorphoSys expects growth from new indications currently being investigated in Phase 3 studies. The company's CEO emphasized the potential of Monjuvi and the focus on maintaining a strong financial position in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
News
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
MorphoSys AG (MOR) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences
-
News
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Rhea-AI Summary
MorphoSys AG (MOR) announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. The study demonstrated significant reductions in spleen size and symptoms, improved measures of anemia, bone marrow fibrosis, and a well-tolerated safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.25%
Tags
clinical trial
News
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Rhea-AI Summary
MorphoSys AG (MOR) announced strong topline results from the Phase 3 MANIFEST-2 study, showing pelabresib's significant improvement in myelofibrosis patients. The combination therapy met the primary endpoint, nearly doubling SVR35 response rate, and demonstrated meaningful anemia improvement. Key secondary endpoints assessing symptom reduction and TSS showed significant improvements for intermediate-risk patients. Safety results were consistent with prior clinical trials. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.35%
Tags
clinical trial
Stock MOR logo
Morphosys AG

Nasdaq:MOR

MOR Rankings

#1635 Ranked by Market Cap
#328 Ranked by Stock Gains
N/A Ranked by Dividends

MOR Stock Data

2.74B
33.15M
15.97%
1.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Planegg

About MOR

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.